Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | FERMT2 | Q96AC1 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27953778 | 0.73 | CYP1A2 (0.59) | NR4A2CYP1A2MAPTKDM4ERAB9A | |
| SCHEMBL12840976 | 0.71 | CYP1A2 (0.68) | NR4A2CYP1A2MAPTKDM4EGAA | |
| SCHEMBL23904649 | 0.71 | CYP1A2 (0.68) | NR4A2CYP1A2MAPTKDM4EMAPK1 | |
| SCHEMBL27831667 | 0.70 | CYP1A2 (0.70) | NR4A2CYP1A2MAPTKDM4EKMT2A | |
| SCHEMBL23070410 | 0.70 | CYP1A2 (0.70) | NR4A2CYP1A2MAPTKDM4EKMT2A | |
| SCHEMBL30016254 | 0.70 | CYP1A2 (0.70) | NR4A2CYP1A2MAPTKDM4EKMT2A | |
| SCHEMBL23340187 | 0.69 | CYP1A2 (0.64) | NR4A2CYP1A2MAPTKDM4EGAA | |
| SCHEMBL30028448 | 0.68 | CYP1A2 (0.68) | NR4A2CYP1A2MAPTKDM4EGAA | |
| SCHEMBL2455864 | 0.68 | CYP1A2 (0.68) | NR4A2CYP1A2MAPTKDM4EGAA | |
| SCHEMBL7656126 | 0.68 | MAPT (0.63) | NR4A2CYP1A2MAPTRAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360365-A1 | SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-11-19 | — | — | US | disclosed |
| US-20200181089-A1 | 4-ANILINO-QUINOLINE COMPOUNDS AS ANTI-CANCER AGENTS | Université Côte d'Azur (FR) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181089-A1 | 4-ANILINO-QUINOLINE COMPOUNDS AS ANTI-CANCER AGENTS | CD274, PDCD1, PDCD1LG2 | NR4A2 1545/4885CYP1A2 820/4885MAPT 1427/4885 |
| US-20200360365-A1 | SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA | MCL1, BCL6, BCL6B | NR4A2 2602/4885CYP1A2 171/4885MAPT 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.